Please select the option that best describes you:

Would you still consider omalizumab for CSU with angioedema in a patient with Factor V Leiden deficiency?   

Omalizumab has been reported as a possible provoking factor for venous thromboembolism.



Answer from: at Academic Institution
Sign in or Register to read more

Answer from: at Academic Institution
Sign in or Register to read more